Mr. Kym Anthony reports

AVIVAGEN ENTERS INTO PARTNERSHIP WITH CSA TO SELL AND DISTRIBUTE OXC-BETA LIVESTOCK IN THE UNITED STATES

Avivagen Inc. has signed a partnership with CSA Animal Nutrition providing for the sales and distribution of OxC-beta livestock by CSA in the United States. Under the terms of the agreement, CSA will co-ordinate commercial-scale validation research with potential customers and fulfill a sales and distribution role with OxC-beta for poultry, swine and dairy cattle in the United States. This agreement provides Avivagen with an experienced partner with numerous established relationships throughout the United States.

"We're very excited to be entering into this important relationship that will bring OxC-beta to this crucial market and allow for the sale of OxC-beta within the United States," said Kym Anthony, chairman and interim chief executive officer, Avivagen. "With their extensive technical experience and relationships and ability to access the U.S. livestock and poultry markets, CSA represents a strong partner for Avivagen. The timing is good given the regulatory process in the U.S. is now completed and we look to add sales and distribution networks in new markets to significantly drive our sales."

This U.S. partnership provides Avivagen with access to 20 per cent of the world's global feed market and encompasses poultry, swine and dairy cattle.

CSA's unique business model provides nutrition solutions and services for meat, milk and egg producers, feed manufacturers, and nutrition consultants. As an independent, science based and customer focused firm, CSA's priorities are driven by nutrition for the animal and economics for its customers, providing quality solutions, services and products for a wide range of customers. In addition to providing core nutrition services, CSA will engage in screening, validating and commercializing emerging nutrition technologies. As an independent firm, CSA has the flexibility and expertise to reach a variety of customers across numerous species, from integrated commercial livestock and poultry production companies and young animal product manufacturers to premix blenders, thereby enhancing the potential adoption and sale of OxC-beta.

About Avivagen Inc.

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, PEI.

About OxC-beta technology and OxC-beta livestock

Avivagen's OxC-beta technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta livestock is currently registered and available for sale in the Philippines, Taiwan, New Zealand, Thailand and United States.

Avivagen's OxC-beta livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta livestock have proven that the product performs as well as, and, some times, in some aspects, better than in-feed antibiotics.

We seek Safe Harbor.